Exhibit 1

 

Joint Filing Statement

 

Statement Pursuant to Rule 13d-1(k)(1)

 

The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Shares of Fennec Pharmaceuticals Inc., together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

 

This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.

 

Dated: February 14, 2025 DG Capital Management, LLC
     
  By: /s/ Dov Gertzulin
    Dov Gertzulin, Managing Member
     
  DG Value Partners II Master Fund, LP
     
  By:

DG Capital Management, LLC, its investment manager

     
  By: /s/ Dov Gertzulin
    Dov Gertzulin, Managing Member
     
  Dov Gertzulin
     
  By: /s/ Dov Gertzulin
    Individually

 

 

 

Fennec Pharmaceuticals (NASDAQ:FENC)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Fennec Pharmaceuticals.
Fennec Pharmaceuticals (NASDAQ:FENC)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Fennec Pharmaceuticals.